Pharmaceutical, biotechnology and medical technologies corporation Johnson & Johnson (NYSE:JNJ) announced on Monday that it has submitted a supplemental Biologics License Application to the US FDA for DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd).
This application seeks approval for treating newly diagnosed multiple myeloma (NDMM) patients ineligible for or deferring autologous stem cell transplant (ASCT).
Data from the Phase 3 CEPHEUS study supports the submission, showing 60.9% of patients achieved minimal residual disease (MRD)-negativity with D-VRd, reducing the risk of progression or death by 43%. D-VRd demonstrated superior response rates and durability compared to the VRd regimen, with a complete response rate of 81.2%. Sustained MRD-negativity also favored D-VRd at 48.7% vs 26.3% for VRd.
The study enrolled 396 patients across 13 countries. Safety profiles for D-VRd were consistent with those of DARZALEX FASPRO and VRd.
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma